GlycoEra
PrivateLast Round
Series B
May 27, 2025
Total Funding Raised
$179M
Company Overview
GlycoEra is a biotechnology company that develops innovative biologics and protein degraders to treat inflammatory, autoimmune, and immune-oncology conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GlycoEra Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
GlycoEra Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 27, 2025 | ||||
| Series A Extension | Jan 5, 2024 | ||||
| Series A | Nov 5, 2021 |
Key People
Founding team and executive leadership
GlycoEra Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Series B |
| Roche Venture Fund | Series B, Series A |
| Sixty Degree Capital | Series B |
| MP Healthcare Venture Management | Series B |
| 5AM Ventures | Series B, Series A Extension, Series A |
| Catalio Capital Management | Series B |
| Roche Venture Fund | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2026
Petra Duda, M.D., Ph.D. appointed as new CMO.
- May 27, 2025
Matthew Hobson of Catalio Capital Management joins the board.
GlycoEra Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about GlycoEra's valuation, stock price, and market status.